Lisette Koeneman

Lilly Deutschland, Germany

Eli Lilly & Company (Employment, Ownership Interest includes stock, stock options, patent or other intellectual property)

Presentation(s):

• Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

  Friday, August 26, 2022
  6:15 PM – 6:20 PM CEST

• Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-like peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study

  Sunday, August 28, 2022
  9:30 AM – 9:45 AM CEST